Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Non-inferiority study of MPFF 1000 mg chewable vs MPFF 500 mg in chronic venous disease
2017-003633-28Phase 3Completed
- Sponsor
- Servier
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of micronized purified flavonoid fraction in chronic venous disease (CVD) and venous stasis (2 arms), sponsored by Servier. Primary endpoint: Lower limb discomfort assessed by eVAS. Started Mar 2018; status: completed.
02
Drugs
micronized purified flavonoid fraction
03
Conditions
chronic venous disease (CVD)venous stasis
Beyond the preview
Go deeper on 2017-003633-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003633-28.